Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study.

Tincello DG, Owen RK, Slack MC, Abrams KR.

BJOG. 2013 Jan;120(2):212-6. doi: 10.1111/1471-0528.12069. Epub 2012 Nov 27.

2.

Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.

Goessaert AS, Everaert KC.

Expert Rev Neurother. 2012 Jul;12(7):763-75. doi: 10.1586/ern.12.61. Review.

PMID:
22853784
3.

Outcomes and patient-based hearing status in conductive hearing loss.

Stewart MG.

Laryngoscope. 2001 Nov;111(11 Pt 2 Suppl 98):1-21. Review.

PMID:
11802001
4.

Botulinum toxin type A for the treatment of lower urinary tract disorders.

Yokoyama T, Chancellor MB, Oguma K, Yamamoto Y, Suzuki T, Kumon H, Nagai A.

Int J Urol. 2012 Mar;19(3):202-15. doi: 10.1111/j.1442-2042.2011.02946.x. Epub 2012 Jan 6. Review.

5.

Endpoints for therapeutic interventions in faecal incontinence: small step or game changer.

Rao SS.

Neurogastroenterol Motil. 2016 Aug;28(8):1123-33. doi: 10.1111/nmo.12905. Review.

PMID:
27440495

Supplemental Content

Support Center